MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
8.93
-0.33 (-3.56%)
Oct 29, 2025, 4:00 PM EDT - Market closed
MeiraGTx Holdings Revenue
MeiraGTx Holdings had revenue of $3.69M in the quarter ending June 30, 2025, with 1,208.87% growth. This brings the company's revenue in the last twelve months to $37.92M, up 366.84% year-over-year. In the year 2024, MeiraGTx Holdings had annual revenue of $33.28M with 137.42% growth.
Revenue (ttm)
$37.92M
Revenue Growth
+366.84%
P/S Ratio
18.28
Revenue / Employee
$99,520
Employees
381
Market Cap
718.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.28M | 19.26M | 137.42% |
| Dec 31, 2023 | 14.02M | -1.90M | -11.95% |
| Dec 31, 2022 | 15.92M | -21.78M | -57.77% |
| Dec 31, 2021 | 37.70M | 22.14M | 142.25% |
| Dec 31, 2020 | 15.56M | 2.27M | 17.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MGTX News
- 22 days ago - MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress - GlobeNewsWire
- 5 weeks ago - MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital - Seeking Alpha
- 2 months ago - MeiraGTx Reports Second Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 6 months ago - MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - GlobeNewsWire
- 6 months ago - MeiraGTx Reports First Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 6 months ago - MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease - GlobeNewsWire
- 6 months ago - Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more - GlobeNewsWire
- 7 months ago - MeiraGTx Holdings: Gaining Regulatory Focus - Seeking Alpha